MRI for Predicting Response and 10-Year Outcome of Neoadjuvant Chemotherapy with or Without Additional Bevacizumab Treatment in HER2-Negative Breast Cancer.

Cancers (Basel) · 2026 · PMC12897187 · PMID 41681863

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, the difference in pCR-rates between the two treatment groups (3/32 in the chemotherapy-only group versus 11/38 in the chemotherapy + bevacizumab group) was close to but did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.